logo
India tightens export rules for medicines to check wide misuse as narcotics in overseas markets

India tightens export rules for medicines to check wide misuse as narcotics in overseas markets

Mint13-05-2025
New Delhi: The Centre has tightened the rules for exports to check the wide abuse of medicines manufactured in India, three officials aware of the matter said. The guidelines are applicable to unapproved and approved new drugs for exports purpose only and manufacturers have to comply with the legal procedures, two officials aware of the matter said.
Also Read | India to boost production of combat medicines
With some of these drugs being used in overseas markets as narcotics, the Central Drugs Standard Control Organization (CDSCO) has introduced a two-step verification for the manufacturer that will be checked at Indian ports.
In addition, the apex drug regulator has made it mandatory for manufacturers to obtain regulatory approval from the importing country for medicines classed as narcotic drugs and psychotropic substances (NDPS).
Also Read | E-pharmacies, chemists at odds as govt mulls a stop to home delivery of drugs
The development comes against the backdrop of unapproved Indian-made drugs being exported to countries in Africa and being rerouted to other destinations.
Under the new rules, a manufacturer has to first obtain a no-objection certificate (NOC) from the Central Licensing Authority. Once approved, the consignment and all related documents will be verified at the port before shipment.
Also Read | You may soon get to buy non-prescription drugs at a friendly neighbourhood store
Earlier, there was no detailed verification of the manufacturer at Indian ports. The manufacturers will have to submit the details of quality of products, manufacturer's name, name of the exporting country and details of the buyer.
These regulations have been made under the relevant provisions of the Drugs and Cosmetics Act, 1940 and Drug Rule, 1945. A guidance document for manufacturers seen by Mint has been issued by CDSCO.
In case of unapproved FDC (fixed dose combination), unapproved NDPS and banned drugs in India, the manufacturer is required to mandatorily get the approval of the importing country's regulator.
'This entire exercise will ensure that only approved consignment will be shipped from India to the destination country. This is one way to have greater vigilance for exports of unapproved and approved new drugs from India," said one of the officials cited above.
Step two involves the procedure for release of consignment at the Indian port office.
'New guidelines have been issued and these requirements were not in place and divided in two steps. The first thing is online documentation to get the NOC and the second step is physical verification at the ports. This will have uniformity and create the system of traceability all throughout the process," said the second official.
As per the department of pharmaceuticals, the Indian pharmaceutical industry is worth approximately $50 billion with over $25 billion of the value coming from exports. About 20% of the global exports in generic drugs are met by India. The country has 10,000 pharmaceutical companies, out of which 2,000 are MSME drug firms.
Queries sent to the health ministry spokesperson remained unanswered.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Was Rishabh Pant the highest-paid skipper of IPL for Rs 27 crore?
Was Rishabh Pant the highest-paid skipper of IPL for Rs 27 crore?

Pink Villa

time34 minutes ago

  • Pink Villa

Was Rishabh Pant the highest-paid skipper of IPL for Rs 27 crore?

Rishabh Pant created history when, in 2024, he became the most expensive player to be ever auctioned and bought for a massive price at the Indian Premier League 2025. Here's a throwback to the historic moment. Back in November 2024, Rishabh Pant quite literally created history when he was acquired by the team Lucknow Super Giants at the IPL 2025 for a record-breaking price. Scenes at the mega auction event held in Saudi Arabia reached the next level when the auction for Pant began at Rs. 2 crores at the marquee set. The player was ultimately won by Team LSG only. Rishabh Pant's auction started a strong bidding war between LSG and DC. Well, the auction for Rishabh Pant in the IPL was not a smooth one, and it initially began with a strong war between teams Delhi Capitals and Lucknow Super Giants for acquiring him. After a few rounds, the bid scaled up to an enormous Rs 20.75 crores by LSG and was sold to the team. However, team DC issued the right-to-match card to buy back Rishabh Pant. But this time, LSG owner Sanjiv Goenka raised the bid to an ultimatum of Rs 27 crores, and Delhi Capitals finally let go and did not contest this high amount any more. Know Rishabh Pant's salary in LSG after being the costliest cricketer While the massive sum of Rs. 27 crores grabbed attention, it must be known that Pant's salary consisted of a few more criteria and contracts that were agreed upon by him and the Lucknow Super Giants. Well, Rishabh Pant has been contracted with the team for a period of three years until the next mega auction takes place for the players of the IPL. Thus, the amount he has been picked for, Pant will receive during these three years after tax deductions. So out of his Rs. 27 crores, the cricketer will be giving away Rs. 8.1 crore as tax to the Indian government from his total contract. The remaining Rs. 18.9 crore will be received by Rishabh Pant in a total of three years, which comes to about Rs. 6.3 crore in a single year. Rishabh Pant's salary in the IPL in case of injuries during a match Interestingly, as per the contract drawn up between Rishabh and Lucknow Super Giants after the mega auction, the star cricketer is liable to receive the full salary even if he gets injured in-between the season and is not able to play any matches further. However, if the cricketer does not get a chance to play in even one match throughout the season, then the team's franchise holds the right to replace him with another player. Rishabh Pant's hilarious reaction to being the most expensive cricketer in IPL history Recently Rishabh graced The Great Indian Kapil Show, where the host and comedian Kapil Sharma reminded him of his massive feat. He asked the cricketer' 'You were sold for ₹27 crore during the IPL 2025 auction. If a player in your team who was bought for ₹2-3 crores scores more runs than you, do you tell him to take some crores from me and score fewer runs than me?'. In response, Rishabh counter-questioned Kapil what the latter would do if some other artist on his show had a better comic timing than him. To this Kapil added that he edits out the parts, leaving Pant in a peal of laughter.

Dr Jitendra Singh launches National BioBank' for personalised healthcare for every Indian
Dr Jitendra Singh launches National BioBank' for personalised healthcare for every Indian

United News of India

time36 minutes ago

  • United News of India

Dr Jitendra Singh launches National BioBank' for personalised healthcare for every Indian

New Delhi, July 6 (UNI) Union Minister of State for Science and Technology and Vice President of CSIR, Dr. Jitendra Singh, today inaugurated the Phenome India National Biobank National aiming to promise personalised healthcare for every Indian based on their genetic background, lifestyle and envirornment. Designed on the lines of the UK Biobank but contextualised for Indian diversity, the biobank will collect and analyse genetic, lifestyle and clinical data from 10,000 individuals across the country. It is housed at the Council of Scientific and Industrial Research - Institute of Genomics and Integrative Biology (CSIR-IGIB) here. Dr Singh who also launched India's first longitudinal population health study on the occasion, said, 'This is a decisive step towards individualised healthcare, one where treatment can be tailored to a person's genetic background, lifestyle and environment.' The Biobank will support long-term research into a host of conditions including diabetes, cardiovascular disorders, rare genetic diseases and cancers, with a view to improve diagnostics, therapeutic targeting and disease prevention strategies, said a statement from the Ministry. Highlighting the unique metabolic and epidemiological characteristics observed in the Indian population, Dr. Singh underscored the need for population-specific strategies. 'Indians may appear lean but still harbour central obesity, a known risk factor for diabetes and cardiovascular diseases,' he noted. 'Our conditions are complex and deeply heterogeneous. This is where the Biobank becomes vital.' CSIR-IGIB's current projects, including indigenous CRISPR trials for sickle cell anaemia, efforts against antimicrobial resistance (AMR), and diagnostics for liver fibrosis and rare disorders, are expected to greatly benefit from the high-resolution health data generated through the Biobank. Calling for enhanced synergy between research institutions, government departments and the private sector, Dr. Singh emphasised the need to bridge lab-based research with social impact. 'Scientific breakthroughs must transition from the bench to the bedside—and ultimately to the marketplace,' he said. Dr. N. Kalaiselvi, Director General of CSIR and Secretary, DSIR, emphasised its potential to evolve into a global benchmark. 'This is a baby step today, but it holds the promise to rival international projects in both scale and depth,' she said. Dr. Kalaiselvi also reiterated CSIR's efforts in developing affordable diagnostics and CRISPR-based therapies in collaboration with tribal communities, particularly for sickle cell anaemia—a disease with high prevalence in certain regions of India. Reflecting on IGIB's pioneering legacy in genomics, Dr. Souvik Maiti, Director of CSIR-IGIB, noted that the institute was the first in India to begin decoding the human genome, even before sequencing tools became widely available. He cited IGIB's development of over 300 genetic diagnostics, its leadership in COVID-19 genome surveillance, and India's first Drug Genome Project. IGIB's expanding research now includes women-centric studies, breast cancer genomics, and innovative work in space biology and AI-assisted pilot fitness assessments in collaboration with the Indian Air Force, said the statement. UNI AJ GNK

Indian hospitality industry protected from AI but needs massive manpower
Indian hospitality industry protected from AI but needs massive manpower

Business Standard

time43 minutes ago

  • Business Standard

Indian hospitality industry protected from AI but needs massive manpower

Hotel chains have partnered with reputed hospitality institutes, participate in campus placement drives but to bridge the talent gap Gulveen Aulakh New Delhi Listen to This Article India's hospitality sector is likely to remain immune to the impact of artificial intelligence (AI), said industry watchers and executives, as it embarks on a CAGR growth of 9.6 per cent over the next five years, on the back of a rebound in tourism. In its latest projections, the World Travel and Tourism Council (WTTC), said that the Indian travel and tourism sector is expected to employ more than 63.9 million by 2035, up from 46.3 million in 2024. 'This is the only industry which may be immune to the impact of AI,' the WTTC chief executive Julia Simpson said,

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store